Ker Yu

5.5k total citations · 1 hit paper
84 papers, 4.5k citations indexed

About

Ker Yu is a scholar working on Molecular Biology, Immunology and Organic Chemistry. According to data from OpenAlex, Ker Yu has authored 84 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Molecular Biology, 19 papers in Immunology and 16 papers in Organic Chemistry. Recurrent topics in Ker Yu's work include PI3K/AKT/mTOR signaling in cancer (45 papers), Protein Kinase Regulation and GTPase Signaling (12 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Ker Yu is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (45 papers), Protein Kinase Regulation and GTPase Signaling (12 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Ker Yu collaborates with scholars based in United States, China and Canada. Ker Yu's co-authors include Robert T. Abraham, Lourdes Toral‐Barza, James J. Gibbons, Judy Lucas, Arie Zask, Boris Shor, Semiramis Ayral‐Kaloustian, Irwin Hollander, Jeroen C. Verheijen and Christina Ravera and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Molecular and Cellular Biology.

In The Last Decade

Ker Yu

83 papers receiving 4.4k citations

Hit Papers

Differential Activation of Peroxisome Proliferator-activa... 1995 2026 2005 2015 1995 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids
    1995 598 citations Ker Yu, William Bayona et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ker Yu United States 36 3.3k 800 631 570 477 84 4.5k
Ching-Shih Chen United States 46 3.3k 1.0× 545 0.7× 920 1.5× 652 1.1× 533 1.1× 83 5.3k
Daniela Trisciuoglio Italy 35 2.9k 0.9× 355 0.4× 1.1k 1.7× 951 1.7× 496 1.0× 88 4.4k
Shripad S. Bhagwat United States 22 2.1k 0.6× 675 0.8× 611 1.0× 417 0.7× 529 1.1× 53 4.0k
Joong Sup Shim Macao 33 3.2k 1.0× 283 0.4× 994 1.6× 792 1.4× 328 0.7× 85 5.0k
Michiaki Kohno Japan 35 3.1k 0.9× 309 0.4× 846 1.3× 531 0.9× 393 0.8× 92 4.5k
Mauricio J. Reginato United States 35 4.2k 1.3× 532 0.7× 1.2k 1.8× 1.1k 1.9× 1.0k 2.1× 63 5.7k
Carlo M. Croce United States 22 2.4k 0.7× 599 0.7× 607 1.0× 389 0.7× 604 1.3× 31 3.6k
Michael H. Cardone United States 21 3.3k 1.0× 248 0.3× 841 1.3× 483 0.8× 610 1.3× 31 4.4k
Hiroshi Yasui Japan 31 3.0k 0.9× 235 0.3× 1.3k 2.1× 415 0.7× 549 1.2× 141 4.7k
John Brognard United States 25 3.7k 1.1× 240 0.3× 1.0k 1.6× 658 1.2× 301 0.6× 50 4.5k

Countries citing papers authored by Ker Yu

Since Specialization
Citations

This map shows the geographic impact of Ker Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ker Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ker Yu more than expected).

Fields of papers citing papers by Ker Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ker Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ker Yu. The network helps show where Ker Yu may publish in the future.

Co-authorship network of co-authors of Ker Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Ker Yu. A scholar is included among the top collaborators of Ker Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ker Yu. Ker Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Xin, et al.. (2024). SMS2 siRNA inhibits pancreatic tumor growth by tumor microenvironment modulation. International Immunopharmacology. 142(Pt A). 113111–113111. 1 indexed citations
2.
3.
4.
Xia, Li, Chenglong Liu, Lian Shen, et al.. (2022). RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers. Journal of Experimental & Clinical Cancer Research. 41(1). 155–155. 33 indexed citations
5.
Feng, Mei, Yan Zhou, Shenglin Mei, et al.. (2021). BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer. Signal Transduction and Targeted Therapy. 6(1). 313–313. 28 indexed citations
6.
Jin, Rui, Liang Liu, Yun Xing, et al.. (2020). Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function. Molecular Cancer Therapeutics. 19(11). 2340–2352. 21 indexed citations
7.
Deng, Yan, Shuhua He, Bin Lou, et al.. (2020). Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer. Acta Pharmacologica Sinica. 42(1). 149–159. 39 indexed citations
8.
Zhang, Qianwen, Yan Zhang, Yaqing Chen, et al.. (2019). A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer. Clinical Cancer Research. 25(12). 3630–3642. 51 indexed citations
9.
Zhao, Hui, et al.. (2018). Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers. Acta Pharmacologica Sinica. 40(2). 257–267. 30 indexed citations
10.
Gopalsamy, Ariamala, Eric M. Bennett, Mengxiao Shi, et al.. (2012). Identification of pyrimidine derivatives as hSMG-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(21). 6636–6641. 44 indexed citations
11.
Yu, Ker, Celine Shi, Lourdes Toral‐Barza, et al.. (2010). Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2. Cancer Research. 70(2). 621–631. 162 indexed citations
12.
Verheijen, Jeroen C., David J. Richard, Kevin J. Curran, et al.. (2010). 2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability. Bioorganic & Medicinal Chemistry Letters. 20(8). 2648–2653. 22 indexed citations
13.
Tsou, Hwei‐Ru, Gary H. Birnberg, Nan Zhang, et al.. (2010). 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorganic & Medicinal Chemistry Letters. 20(7). 2259–2263. 19 indexed citations
14.
Yu, Ker, Lourdes Toral‐Barza, Celine Shi, et al.. (2009). Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin. Cancer Research. 69(15). 6232–6240. 277 indexed citations
15.
Verheijen, Jeroen C., Ker Yu, Lourdes Toral‐Barza, Irwin Hollander, & Arie Zask. (2009). Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K. Bioorganic & Medicinal Chemistry Letters. 20(1). 375–379. 32 indexed citations
16.
Richard, David J., Jeroen C. Verheijen, Kevin J. Curran, et al.. (2009). Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability. Bioorganic & Medicinal Chemistry Letters. 19(24). 6830–6835. 42 indexed citations
17.
Shor, Boris, Weiguo Zhang, Lourdes Toral‐Barza, et al.. (2008). A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis. Cancer Research. 68(8). 2934–2943. 102 indexed citations
18.
Toral‐Barza, Lourdes, et al.. (2005). Characterization of the cloned full-length and a truncated human target of rapamycin: Activity, specificity, and enzyme inhibition as studied by a high capacity assay. Biochemical and Biophysical Research Communications. 332(1). 304–310. 33 indexed citations
19.
Graziani, Edmund I., Jeffrey E. Janso, Ker Yu, et al.. (2004). Isolation, Structure Determination and Biological Activity of 15-Deoxo-7,32-O-didesmethylrapamycin from the Soil Actinomycete LL-D45042. The Journal of Antibiotics. 57(7). 462–464.
20.
Yu, Ker, William Bayona, Caleb B. Kallen, et al.. (1995). Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids. Journal of Biological Chemistry. 270(41). 23975–23983. 598 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ching-Shih Chen Breakdown of academic impact, for papers by Daniela Trisciuoglio Breakdown of academic impact, for papers by Shripad S. Bhagwat Breakdown of academic impact, for papers by Joong Sup Shim Breakdown of academic impact, for papers by Michiaki Kohno Breakdown of academic impact, for papers by Mauricio J. Reginato Breakdown of academic impact, for papers by Carlo M. Croce Breakdown of academic impact, for papers by Michael H. Cardone Breakdown of academic impact, for papers by Hiroshi Yasui Breakdown of academic impact, for papers by John Brognard
Rankless by CCL
2026